Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AP-325 in Peripheral Post-surgical Neuropathic Pain
2019-003502-28Phase 2Completed
- Sponsor
- Algiax Pharmaceuticals
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Peripheral neuropathic pain comparing AP-325 with Placebo (2 arms). Primary endpoint: Change in 5-day average pain intensity (PI-NRS) from Baseline to Day 10. Started Dec 2019; status: completed.
02
Drugs
AP-325
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on 2019-003502-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003502-28.